Op2Lysis
Entity

  • Op2Lysis

    Created in 2016
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    770

  • Activities

    biotech deeptech healthtech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Bd Henri Becquerel, 14000 Caen, France

    Caen

    France

  • Employees

    Scale: 2-10

    Estimated: 8

  • SIREN

    819697707

  • Engaged corporates

    4
    1 4

  • Added in Motherbase

    4 months, 2 weeks ago
Description
  • Value proposition

    A New Hope for Hemorrhagic Stroke

    Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North America and Europe.

    Cardiovascular, Cérébrovascular, and drug development

  • Original language

    Op2Lysis développe de nouveaux traitements pour les patients atteints de thromboses au niveau cérébrovasculaire, avec un premier focus sur la forme hemorragique de l’AVC. En effet, il n'y a pas de solution thérapeutique actuellement approuvée et disponible pour les victimes d'un AVC hémorragique. L'entreprise développe sa plateforme NANOp2Lysis(r), l'association d'une technologie de vectorisation de rupture, d'un savoir-faire industriel permettant des productions de qualité clinique, et d'une expertise préclinique incluant la mise en place de modèles prédictifs et translationnels, une première dans ce domaine. O2L-001, le premier produit issu de cette technologie va entrer prochainement en toxicologie réglementaire dans l’objectif d’une demande d’autorisation d’essai clinique chez le patient en Amérique du Nord et en Europe.

  • Op2Lysis | Innovative treatment for hemorrhagic stroke

    Op2lysis is a biotechnology company that develops innovative medicines for the treatment of hemorrhagic stroke, with its proprietary technology NANOp2Lysis®.

    • https://www.op2lysis.com/
Corporate interactions BETA
Corporate TypeTweets Articles
Noshaq
Noshaq
Venture Capital and Private Equity Principals
Noshaq
Venture Capital and Private Equity Principals 		Other

29 Feb 2024


WiSEED
WiSEED
Crowdfunding, Financial Services
WiSEED
Crowdfunding, Financial Services 		Other

22 Jan 2024


Business France
Business France
National and local authorities, Government Administration
Business France
National and local authorities, Government Administration 		Other

30 Sep 2023


Medicen Paris Region
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations
Medicen Paris Region
Public business cluster, French Cluster, Civic and Social Organizations 		Other

28 Feb 2024


Similar entities
Last news
Show all articles
Social network dynamics